Mylan Pharmaceuticals Inc. announced on Friday the U.S. approval of its ANDA for saxagliptin and metformin, initiating a new competitive entry into the expanding diabetes market segment. This regulatory progress positions the manufacturer to capture market share from established Theraset (Omar Lilium) products facing postmarketing concerns.